7.2.2. role lymph node dissection locally-advanced rcc. locally-advanced rcc, role lnd still controversial. available rct demonstrated survival benefit patients undergoing lnd trial mainly included organ-confined disease cases . setting locally-advanced disease, several retrospective papers srs addressed topic contradictory results. sr meta-analyses could confirm survival benefit patients high risk progression treated lnd . recent sr meta-analyses showing survival benefit patients locally-advanced disease treated lnd . specifically, thirteen studies patients lnd non-lnd identified included analysis. subgroup locally-advanced rcc (ct3-t4nxm0), lnd showed significantly better os rate patients undergone lnd compared without lnd (hr: 0.73, 95% ci: 0.60-0.90, p = 0.003). 7.2.2.1. management clinically negative lymph nodes (cn-) locally-advanced rcc case cn-, probability finding pathologically-confirmed ln metastases ranges 0-25%, depending mainly primary tumour size presence distant metastases . case clinically- negative lns (cn-) imaging, removal lns justified visible palpable surgery , least staging, prognosis, adjuvant therapy follow-up implications, although benefit terms cancer control yet demonstrated . 7.2.2.2. management clinically positive lymph nodes (cn+) locally-advanced rcc case cn+, probability identify pathologically-confirmed ln metastases ranges 10.3% (ct1 tumours) 54.5% case locally-advanced disease. cn+, removal visible palpable nodes lnd justified , least staging, prognosis, adjuvant therapy follow-up implications, although benefit terms cancer control yet demonstrated . whether extend lnd case lymphadenopathy (cn1) remains controversial. addition retrospective data showed resected isolated macrospcopical lympnode metastises (pn1) time systemic progression median 4.2 months .